X
<
Asian
Pre-Market Report: Global Markets Are Mixed on December 13

On December 13, the Shanghai Composite Index rose 0.68% and closed the day at 3,303.04. The SPDR S&P China (GXC) fell 1.3% on December 12.

SCG-stk-1
SCANA’s Nuclear Mess Continues to Push the Stock Down

The stock for SCANA (SCG), which is based in Cayce, South Carolina, is continuing to fall over its nuclear power plant issues. The stock fell more than 6% on December 11, 2017.

etf performance
How US Tax Reforms Could Impact the Healthcare Industry

The tax reform bills passed by the US House and Senate reduce the corporate tax rate from 35.0% to 20.0%. According to Credit Suisse, healthcare companies pay corporate taxes as high as 30.2%.

Major-producers-June-13-2-1
Crude Oil Prices Could End 2017 on a High Note

US crude (UWT) (SCO) oil futures contracts for January delivery rose 1.1% to $57.99 per barrel on December 11, 2017.

RECENT Healthcare RESEARCH

1
The Pharmacy Flurry: CVS Bids for Aetna

According to a recent report by the Wall Street Journal, America’s largest pharmacy chain, CVS Health (CVS), is in talks to buy Aetna (AET) for more than $66 billion.

Chart-01-EPS-4-1
Ahead of Pfizer's 3Q17 Results: Gauging the Estimates

For 3Q17, Wall Street analysts estimate that Pfizer will report EPS (earnings per share) of $0.64 on revenues of $13.18 billion.

Chart-01-EPS-5-1
Allergan's 3Q17 Earnings: What You Can Expect

Allergan (AGN) is one of the leading pharmaceutical companies, and it’s set to release its 3Q17 earnings on November 1.

recommendations
How Intuitive Surgical Continues Its March to Growth

As of October 26, of the 18 brokerage companies covering ISRG stock, 11 (~61%) recommend a “buy,” while six (~33%) recommend a “hold.”

Vertex-Revenues-1
Vertex Pharmaceuticals Raises 2017 Revenue Guidance after 3Q17 

In 3Q17, Vertex Pharmaceuticals (VRTX) generated revenues of $578.0 million, which was a ~40.0% rise YoY and a ~6.0% rise QoQ.

Graph-1-5-1
What Are Ionis Pharmaceuticals' Key Growth Drivers?

In its 2Q17 earnings conference call, Ionis Pharmaceuticals (IONS) raised its guidance for 2017 pro forma operating income.

Biogen-revenues-2-1
How 3Q17 Turned Out for Biogen

In 3Q17, Biogen (BIIB) generated revenue of ~$3.1 billion, which reflected ~4% growth year-over-year.

Chart-01-EPS-3-1
What Analysts Expect from Bristol-Myers Squibb's 3Q17 Earnings

Bristol-Myers Squibb (BMY) is set to release its 3Q17 earnings on October 27, 2017. Analysts estimate the company will post EPS of $0.77 and revenues of $5,196 million for 3Q17.

AbbVie-revenues-1-1
AbbVie's Recent Performance and Growth Drivers

In 1H17, AbbVie (ABBV) reported revenues of around $13.5 million, compared to $12.4 million in 1H16. In 1Q17 and 2Q17, AbbVie reported revenues of around $6.5 million and $6.9 million, respectively.

Chart-001-1
What Investors Can Expect from Merck’s 3Q17 Earnings Release

Analysts estimate Merck’s gross profit margin to come in at 75.8% for 3Q17, a 0.5% increase as compared to its gross profit margin in 3Q16.

Chart-01-1
What to Expect from Eli Lilly’s 3Q17 Earnings

For 3Q17, analysts estimate that Eli Lilly will post EPS of $1.03 on revenues of $5.5 billion.

Valeant-Pharmaceuticals-revenues-1
Valeant Pharmaceuticals: How It Performed in 1H17

In 1H17, Valeant Pharmaceuticals International (VRX) reported revenues of $4.3 billion compared to $4.7 billion in 1H16. In 2Q17, its revenues were $2.2 billion.

Chart-011-GILD-1
US Pharmaceutical Companies in 3Q17 (Part 2)

Gilead Sciences stock has risen ~15.2% in 3Q17 and 13.9% year-to-date as of October 20, 2017.

recommendations
Boston Scientific's 3Q17 Results Are Coming: What's Expected?

BSX stock has been performing well recently, and investor confidence appears to have ridden on innovative product launches and strong 2Q17 results.

Chart-001-MA-1
US Pharma in 3Q17: A Key Performance Overview

Calendar 3Q17 saw several major mergers and acquisitions in the US pharmaceutical industry.

Analysts-Ratings-3-1
What's Gilead Sciences Cooking up Now?

Of the 28 analysts tracking Gilead Sciences in October 2017, three have recommended a “strong buy,” while 11 have recommended a “buy.”

Graph-1-3-1
The Medicines Company in 2017: Should We Be Interested?

In 2Q17, The Medicines Company (MDCO) reported revenues of $18.7 million, which is a fall of 66.0% on a YoY (year-over-year) basis.

Neuro
How Is Neurocrine Biosciences Positioned Now?

In the first half of 2017, Neurocine Biosciences (NBIX) generated revenues of $6.3 billion and reported expenses on the cost of product sales of $61.0 million.

intralipid-iv-emulsion-1-1
Investor Update: Recent Developments at Baxter International

On October 5, 2017, Baxter International (BAX) announced the voluntary recall of a shipment from a lot of Intralipid 20% IV Fat Emulsion, 100 mL. This lot was distributed from August 11 to August 31, 2017.

Chart-01-EPS-1
What to Expect from Johnson & Johnson’s 3Q17 Earnings

Johnson & Johnson (JNJ) is set to release its 3Q17 earnings on October 17. Analysts expect JNJ’s 3Q17 revenues to rise ~8.3% to ~$19.3 billion compared to ~$17.8 billion for 3Q16.

X

Please select a profession that best describes you: